GMT Capital Corp Sells 1,036,655 Shares of OptiNose, Inc. (NASDAQ:OPTN)

GMT Capital Corp cut its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,047 shares of the company's stock after selling 1,036,655 shares during the period. GMT Capital Corp owned approximately 0.74% of OptiNose worth $495,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC boosted its position in OptiNose by 33.7% in the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company's stock worth $870,000 after purchasing an additional 326,918 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company's stock.

Analysts Set New Price Targets

OPTN has been the subject of several recent research reports. Piper Sandler restated a "neutral" rating and set a $9.00 target price (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st. Lake Street Capital cut OptiNose from a "buy" rating to a "hold" rating and decreased their target price for the stock from $17.00 to $9.00 in a report on Thursday, March 20th. Finally, HC Wainwright reissued a "neutral" rating and set a $9.00 price target (down previously from $18.00) on shares of OptiNose in a report on Friday, March 21st.

Insiders Place Their Bets

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the completion of the transaction, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. This represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 8,213 shares of company stock worth $43,643 in the last three months. 2.30% of the stock is owned by company insiders.

OptiNose Stock Performance

Shares of NASDAQ OPTN traded up $0.03 during midday trading on Monday, reaching $9.31. The stock had a trading volume of 8,023 shares, compared to its average volume of 61,673. OptiNose, Inc. has a 12-month low of $4.82 and a 12-month high of $20.03. The stock has a 50-day moving average of $7.65 and a 200-day moving average of $7.61. The company has a market capitalization of $94.23 million, a price-to-earnings ratio of -2.22 and a beta of -0.87.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.67. The business had revenue of $21.47 million during the quarter, compared to analysts' expectations of $21.02 million. As a group, analysts forecast that OptiNose, Inc. will post -3.22 EPS for the current fiscal year.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.